Sandmeier M, Ricci F, To D, Lindner S, Stengel D, Schifferle M, et al
Not applicable
Diabetes Care, 48 (1 Suppl 1), S167S180
GLP-1 medications are designed to activate GLP-1 receptors in the body
The NICE criteria are as follows: NICE recommends GLP-1 analogues or Tirzepatide (Mounjaro) for the treatment of adults with type 2 diabetes alongside diet and exercise when diabetes is insufficiently controlled, only if: triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and a person has a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or a person has a BMI of less than 35 kg/m2, and: Insulin therapy would have significant occupational implications, or Weight loss would benefit other significant obesity-related complications
[1] Our Score: 3/5 Our score is based on the latest medical data, customer feedback, and clinic policies